# Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants

> **NCT03239561** · EARLY_PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 15 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** [18F]MNI-1020

## Key facts

- **NCT ID:** NCT03239561
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-06
- **Primary completion:** 2018-04-30
- **Final completion:** 2018-04-30
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2025-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03239561

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03239561, "Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03239561. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*